Granted 180 extension per new 8K
$Brainstorm Cell Therapeutics(BCLI.US$ On June 3, 2024, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, the Nasdaq Hearing Panel had granted the Company a temporary exception until October 21, 2024 to, if necessary, effect the reverse stock split and thereafter regain compliance with the Minimum Bid Price Requirement. The Nasdaq Hearing Panel noted that the temporary exception was granted based upon the Company’s representation that it would complete a reverse stock split, if necessary, no later than October 7, 2024. The Company prioritizes regaining compliance with the Minimum Bid Price Requirement through other measures before resorting to a reverse stock split. However, in the event the Company fails to achieve compliance by mid-August 2024, it will be required to undertake a reverse stock split to regain compliance by the October 21, 2024 deadline. In the event the Company fails to regain compliance with the Minimum Bid Price Requirement by October 21, 2024, its securities will be delisted.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
